This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Chakravarti A , Winter K , Wu CL , Kaufman D , Hammond E , Parliament M , Tester W , Hagan M , Grignon D , Heney N , Pollack A , Sandler H , Shipley W
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group
International Journal of Radiation Oncology Biology Physics. 2005 ;62(2) :309-317
AbstractPurpose: Erb-1 (epidermal growth factor receptor, EGFR) and Erb-2 (Her-2) are two of the best characterized members in the EGFR pathway. In many tumor types, overexpression of these proteins is associated with enhanced malignant potential. Our objective in this study was to investigate the clinical relevance of EGFR and Her-2 expression in bladder cancer cases from four prospective Radiation Therapy Oncology Group (RTOG) bladder preservation trials using cisplatin-containing chemoradiation (RTOG 8802, 8903, 9506, and 9706). Methods and Materials: Tumors from 73 cases from patients with muscle-invading T2-T4a bladder cancers had slides interpretable for EGFR staining; 55 cases had slides interpretable for Her-2 staining. Additionally, the respective prognostic values of p53, pRB, and p16 immunostaining were concomitantly examined. Staining and interpretation of staining were done in a blinded manner, without knowledge of clinical outcome. Staining was judged as positive or negative. Subsequently, staining was correlated with clinical outcome. Results: On univariate analysis, EGFR positivity was significantly associated with improved overall survival (p = 0.044); disease-specific survival (DSS) (p = 0.042); and DSS with intact bladder (p = 0.021). There was also a trend for association between EGFR expression and reduced frequency of distant metastasis (p = 0.06). On multivariate analysis adding tumor stage, tumor grade, whether a visibly complete transurethral resection of bladder tumor (TURBT) was done or not, and patient age to the model, EGFR positivity was significantly associated with improved DSS. On univariate analysis, Her-2 positivity was significantly associated with reduced complete response (CR) rates (50% vs. 81%, p = 0.026) after chemoradiation which remained significant on multivariate analysis. The other markers examined in this study were not found to have any prognostic value in this setting. Conclusion: Epidermal growth factor receptor expression appears to correlate significantly with improved outcome in bladder cancer, whereas Her-2 expression is significantly associated only with reduced CR rates after chemoradiation. Further investigations are warranted into how EGFR family members regulate response to chemoradiation in bladder cancer and their potential therapeutic implications. © 2005 Elsevier Inc.
Notes03603016 (ISSN) Cited By: 1; Export Date: 25 May 2006; Source: Scopus CODEN: IOBPD; DOI: 10.1016/j.ijrobp.2004.09.047 Language of Original Document: English Correspondence Address: Chakravarti, A.; Massachusetts General Hospital; Department of Radiation Oncology; Founders House; 100 Blossom Street Boston, MA 02114, United States; email: email@example.com Chemicals/CAS: cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; epidermal growth factor receptor 2, 137632-09-8; fluorouracil, 51-21-8; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; vinblastine, 865-21-4, Antineoplastic Agents; Cisplatin, 15663-27-1; Protein p16; Protein p53; Receptor, Epidermal Growth Factor, EC 188.8.131.52; Receptor, erbB-2, EC 184.108.40.206; Retinoblastoma Protein References: Baselga, J., Mendelsohn, J., The epidermal growth factor receptor as a target for therapy in breast carcinoma (1994) Breast Cancer Res Treat, 29, pp. 127-138; Baselga, J., The EGFR as a target for anticancer therapy--focus on cetuximab (2001) Eur J Cancer, 37 (4 SUPPL.), pp. 16-S22; Bianco, C., Bianco, R., Tortora, G., Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase a antisense oligonucleotide (2000) Clin Cancer Res, 6, pp. 4343-4350; Ciardielllo, F., Bianco, R., Damiano, V., Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 (1999) Clin Cancer Res, 5, pp. 909-916; Abdul-Manan, N., Aghazadeh, B., Liu, G.A., Structure of Cdc42 in complex with the GTPase-binding domain of the Wiskott-Aldrich syndrome' protein (1999) Nature, 399, pp. 379-383; Grandis, J.R., Chakraborty, A., Melhem, M.F., Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous cell carcinoma but not normal mucosal epithelial cells (1997) Oncogene, 15, pp. 409-416; Esteller, M., Garcia-Foncillas, J., Andion, E., Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents (2000) N Engl J Med, 343, pp. 1350-1354; Hidalgo, A., Sanz-Rodriguez, F., Rodriguez-Fernandez, J.L., Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells (2001) Exp Hematol, 29, pp. 345-355; Beenken, S.W., Sellers, M.T., Huang, P., Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: Modulation by 13-cis retinoic acid (1999) Head Neck, 21, pp. 566-573; Endo, S., Zeng, Q., Burke, N.A., TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo (2000) Gene Ther, 7, pp. 1906-1914; Milas, L., Mason, K., Hunter, N., In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody (2000) Clin Cancer Res, 6, pp. 701-708; Chakravarti, A., Chakladar, A., Delaney, M.A., The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a ras-dependent manner (2002) Cancer Res, 62, pp. 4307-4315; Chakravarti, A., Loeffler, J.S., Dyson, N.J., Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling (2002) Cancer Res, 62, pp. 200-207; O'Rourke, D., Kao, G.D., Singh, N., Conversion of a radio-resistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells (1998) Proc Natl Acad Sci USA, 95, pp. 10842-10847; Altiok, S., Batt, D., Altiok, N., Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells (1999) J Biol Chem, 274, pp. 32274-32278; Harari, P.M., Huang, S.-M., Combining EGFR inhibitors with radiation or chemotherapy: Will pre-clinical studies predict clinical results? (2004) Int J Radiat Oncol Biol Phys, 58, pp. 976-983; Hackel, P.O., Zwick, E., Prenzel, N., Epidermal growth factor receptors: Critical mediators of multiple receptor pathways (1999) Curr Opin Cell Biol, 11, pp. 184-189; Woodburn, J.R., The epidermal growth factor receptor and its inhibition in cancer therapy (1999) Pharmacol Ther, 82, pp. 241-250; Davis, I.D., MacRae Dell, K., Sweeney, W.E., Can progression of autosomal dominant or autosomal recessive polycystic kidney disease be prevented? (2001) Semin Nephrol, 21, pp. 430-440; Haas-Kogan, D., Shalev, N., Wong, M., Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC (1998) Curr Biol, 8, pp. 1195-1198; Levitzki, A., Targeting signal transduction for disease therapy (1996) Curr Opin Cell Biol, 8, pp. 239-244; Schenk, P.W., Snaar-Jagalska, B.E., Signal perception and transduction: The role of protein kinases (1999) Biochim Biophys Acta, 1449, pp. 1-24; Schlegel, J., Piontek, G., Budde, B., The akt/protein kinase B-dependent anti-apoptotic pathway and the mitogen-activated protein kinase cascade are alternatively activated in human glioblastoma multiforme (2000) Cancer Lett, 158, pp. 103-108; Salomon, D.S., Brandt, R., Ciardielllo, F., Epidermal growth factor-related peptides and their receptors in human malignancies (1995) Crit Rev Oncol Haematol, 19, pp. 183-232; Nelson, J.M., Fry, D.W., Akt, MAPK (Erk 1,2) and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition (2001) J Biol Chem, 276, pp. 14842-14847; Nunez, G., Del Peso, L., Linking extracellular survival signals and the apoptotic machinery (1998) Curr Opin Neurobiol, 8, pp. 613-618; Moscatello, D.K., Montgomery, R.B., Sundareshan, P., Transformation and altered signal transduction by a naturally occurring mutant EGF receptor (1996) Oncogene, 13, pp. 85-96; Hashimoto, A., Kurosaki, M., Gotoh, N., Shc regulates epidermal growth factor-induced activation of the JNK signaling pathway (1999) J Biol Chem, 274, pp. 20139-20143; Haas-Kogan, D.A., Dazin, P., Hu, L., P53-Independent apoptosis: A mechanism of radiation-induced cell death of glioblastoma cells (1996) Cancer J Sci Am, 2, p. 114; Chaudhary, L.R., Hruska, K.A., The cell survival signal akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells (2001) J Cellular Biochem, 81, pp. 304-311; Ahrendt, S.A., Halachmi, S., Chow, J.T., Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array (1999) Proc Natl Acad Sci U S a, 96, pp. 7382-7387; Chen, J., Wu, W., Tahir, S.K., Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth (2000) Neoplasia, 2, pp. 235-241; Bowers, G., Reardon, D.B., Hewitt, T., The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells (2001) Oncogene, 20, pp. 1388-1397; Bonner, J.A., Raisch, K.P., Trummell, H.Q., Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers (2000) J Clin Oncol, 18, pp. 47s-53s; Balaban, N., Moni, J., Shannon, M., The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation (1996) Biochim Biophys Acta, 1314, pp. 147-156; Dominguez-Escrig, J.L., Kelly, J.D., Neal, D.E., Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer (2004) Clin Cancer Res, 10, pp. 4874-4884; Nutt, J.E., Lazarowicz, H.P., Mellon, J.K., Gefitinib inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2 (2004) Br J Cancer, 90, pp. 1679-1685; Tester, W., Caplan, R., Heaney, J., Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802 (1996) J Clin Oncol, 14, pp. 119-126; Rozycka, M., Lu, Y.J., Brown, R.A., CDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12 (1998) Genomics, 54, pp. 569-574; Kaufman, D.S., Winter, K.A., Shipley, W.U., The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response (2000) Oncologist, 5, pp. 471-476; Hagan, M.P., Winter, K.A., Kaufman, D.S., Initial report of a phase I/II trial of bladder conservation employing TURB, accelerated radiation sensitized with cisplatin, followed by adjuvant MCV (2003) Int J Radiat Oncol Biol Phys, 57, pp. 665-672; Chen, J., Hanafusa, T., Wang, L.-H., Ala-Gly mutation in the putative catalytic loop confers temperature sensitivity on Ros, insulin receptor, and insulin-like growth factor I receptor protein-tyrosine kinases (1994) Proc Nat Acad Sci, 91, pp. 321-325; Grignon, D.J., Caplan, R., Sarkar, F.H., P53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610 (1997) J Natl Cancer Inst, 89, pp. 158-165; Sarkis, A.S., Dalbagni, G., Cordon-Cardo, C., Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression (1993) J Natl Cancer Inst, 85, pp. 53-59; Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations (1958) J Am Stat Assoc, 53, pp. 457-481; Mantel, N., Evaluation of survival data and two new rank order statistics arising in its consideration (1966) Cancer Chem Rep, 5, pp. 163-170; Gaynor, J.J., Feuer, E.J., Tan, C.C., On the use of cause-specific and conditional failure probabilities (1993) J Am Stat Assoc, 88, pp. 400-409; Gray, R.J., A class of K-sample tests for comparing the cumulative incidence of a competing risk (1988) Ann Stat, 16, pp. 1141-1154; Seigne, J.D., Dayton, S.H., Zhang, D.S., The p53 tumor suppressor gene as a potential prognostic marker in invasive bladder cancer (1992) J Urol, 147, pp. 338A; Lipponen, P., Eskelinen, M., Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis (1994) Br J Cancer, 69, pp. 1120-1125; Mellon, K., Wright, C., Kelly, P., Long-term outcome related to epidermal growth factor receptor status in bladder cancer (1995) J Urol, 153, pp. 919-925; Amagase, H., Tamura, K., Hashimoto, K., Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice (1990) J Pharmacobiodyn, 13, pp. 263-268; Tokunaga, H., Shariat, S., Green, A.E., Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens (2001) Int J Radiat Oncol Biol Phys, 51, pp. 16-22; Schultz, T.K., Herr, H.W., Zhang, Z.F., Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival in patients treated with MVAC with 5 year follow-up (1994) J Clin Oncol, 12, pp. 1394-1401; Friedman, H.S., Petros, W.P., Friedman, A.H., Irinotecan therapy in adults with recurrent or progressive malignant glioma (1999) J Clin Oncol, 17, pp. 1516-1525; Horwich, A., Pendlebury, S., Dearnaley, D.P., Organ preservation in bladder cancer (1995) Eur J Cancer, 31, p. 208; Ang, K., Berkey, B., Tu, X., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma (2002) Cancer Res, 62, pp. 7350-7356; Chakravarti, A., Loeffler, J.S., Dyson, N.J., Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through the continued activation of phosphoinositide 3-kinase signaling (2002) Cancer Res, 62, pp. 200-207; Elledge, R., Green, S., Ciocca, D., Her-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study (1998) Clin Cancer Res, 4, pp. 7-12; Del Muro, X.G., Condom, E., Vigues, F., P53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined modality approach (2004) Cancer, 100, pp. 1859-1867.